A study of the antipsychotic drug, Risperdal, in children with disruptive behavior disorder found that “children given placebos and those given Risperdal both improved significantly” according to an article in the New York Times titled “Research Center Tied to Drug Company”. However, the draft abstract for the study that was sent from Dr. Gahan Pandina, a Johnson & Johnson executive, to the lead author of the study, world-renowned child psychiatrist, Joseph Biederman, MD from Harvard University, who has helped fuel the 40-fold increase in the diagnosis of bipolar disorder in children, and the rapid rise in the use of powerful, risky and expensive antipsychotic drugs in children, stated that “only the children given Risperdal improved, while those given placebos did not” according to the New York Times article. “I will review this morning,” responded Dr. Biederman, according to the documents. “I will be happy to sign the forms if you could kindly send them to me.”
© Copyright 2003-2012 - Larry Hobbs - All Rights Reserved.